International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Janssen Initiates First-of-its-kind Clinical Study to Bridge Critical Gaps in Care for People of Color With Moderate to Severe Plaque Psoriasis

news_janssen blog image
More than 8 million Americans experience the physical, psychological, and emotional toll of psoriasis, but people of color experience additional challenges due to limited medical research, education, and underrepresentation in clinical studies. To help address these critical gaps, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of VISIBLE. VISIBLE is a first-of-its-kind, large-scale prospective clinical study dedicated to generating key disease insights among Black, Hispanic, Asian, Indigenous, and other people of color. This study reinforces Janssen’s commitments to inclusive clinical research and addressing health inequities.
Janssen J & J logo

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

IPC 2023 Think Tank Meeting Report Published in JID Innovations

Improving Medical Adherence in Psoriasis Treatments

Shining a Spotlight: Catching up with 2018 IPC Fellow Filip Rob, MD, PhD

Also Read

genetic insights

IPC 2023 Think Tank Meeting Report Published in JID Innovations

Read key highlights from the 2023 International Psoriasis Council (IPC) Think Tank Meeting, summarizing the evolving understanding of psoriasis management, genetic insights, and treatment strategies presented in the Gunnar Lomholt Symposium. Access the full report on the IPC website and published in JID Innovations.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.